AgingResearch.NewsJoin free

OT-82

Intervention

1 paper studies it1 more mentions it3 findings

PubChem

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: National Cancer Institute and 3 more
  • 3 of 3 findings with company ties
  • Animals1

Outcomes

3

Glycolysis

downin mice1

1 study

  1. OT-82 inhibits glycolysis in mice.

    “OT-82 treatment of HLRCC xenograft tumors in vivo inhibited glycolytic flux as demonstrated by reduced lactate/pyruvate ratio”

    Animalsin HLRCC xenograft tumors in vivo

    Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82

    Molecular cancer therapeutics

More on Glycolysis

Tumor growth

downin mice1

1 study

  1. OT-82 decreases tumor growth in mice.

    “Moreover, NAMPT inhibition by OT-82 in two HLRCC xenograft models resulted in severely reduced tumor growth.”

    Animalsin two HLRCC xenograft models

    Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82

    Molecular cancer therapeutics

Cell viability

downin human cells1

1 study

  1. OT-82 decreases cell viability in human cells.

    “HLRCC cell line viability was significantly decreased in both 2D and 3D in vitro cultures in response to the clinically relevant NAMPT inhibitor OT-82.”

    Cellsin 2D and 3D in vitro cultures of HLRCC cell lines

    Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82

    Molecular cancer therapeutics

Latest

Related